Nurix Adoptive Cell Therapy (NxACT)
Drug-Enhanced Cell Therapy to Improve Patient Outcomes
Targeted Protein Modulation can improve the expansion and quality of cell therapy products, and Nurix is focusing on applying it in two ways under our Nurix Adoptive Cell Therapy or NxACT approach: drug-enhanced tumor infiltrating lymphocytes (DeTIL) and drug-enhanced chimeric antigen receptor T cells (DeCART). Our lead cell therapy program called DeTIL-0255 uses our proprietary ex vivo CBL-B inhibitor, NX-0255, to enhance the activity of tumor infiltrating lymphocytes.
Nurix is pursuing internal development of DeTIL-0255 as its lead DeTIL program. More on DeTIL
Nurix formed a subsidiary called DeCART in collaboration with CAR-T experts from the University of Pennsylvania. Visit DeCART